Drug Profile
DS 1040
Alternative Names: DS-1040b; DS1040Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Antithrombotics; Cardiovascular therapies
- Mechanism of Action Carboxypeptidase U inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Pulmonary embolism; Stroke
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for phase-I development in Stroke in Japan (IV, Infusion)
- 19 Jan 2020 Daiichi Sankyo completes phase I clinical trials in Stroke in Japan (IV) (JapicCTI-173612) (NCT03198715)
- 05 Aug 2019 Daiichi Sankyo completes a phase-I/II clinical trial in Pulmonary embolism (Adjunctive treatment, In the elderly, In adults) in Spain, Netherlands, Italy, Germany, France, France, Belgium, USA and Austria (IV) (NCT02923115)